Pediatric Nephrology

, Volume 28, Issue 5, pp 737–743

Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndrome

  • Nicholas J. A. Webb
  • Shahnaz Shahinfar
  • Thomas G. Wells
  • Rachid Massaad
  • Gilbert W. Gleim
  • Christine McCrary Sisk
  • Chun Lam
Original Article



A previous subgroup analysis of a 12-week, double-blind study demonstrated that losartan significantly lowered proteinuria versus placebo and amlodipine and was well tolerated in children (1–17 years old) with proteinuria secondary to Alport syndrome. The present subgroup analysis of the open-label, extension phase of this study assessed the long-term efficacy and tolerability of losartan versus enalapril.


Patients who had completed the double-blind study were re-randomized to losartan or enalapril and followed for proteinuria and renal function for up to 3 years.


Twenty-seven patients with Alport syndrome were randomized to losartan (0.44-2.23 mg/kg/day; n = 15) or enalapril (0.07-0.72 mg/kg/day; n = 12). The least-squares (LS) mean percent change from week 12 in urinary protein to creatinine ratio (UPr/Cr was +1.1 % in the losartan group versus a further 13.9 % reduction in the enalapril group (GMR [95 % CI] = 1.2 [0.7, 2.0]); the LS mean change from week 12 in estimated glomerular filtration rate (eGFR) was −6.4 ml/min/1.73 m2 in the losartan group versus −9.1 ml/min/1.73 m2 in the enalapril group. The adverse event incidence was low and comparable in both treatment groups.


In children with proteinuria secondary to Alport syndrome, losartan maintained proteinuria reduction, and enalapril produced a further proteinuria reduction over the 3-year study period. Both agents were generally well tolerated.


Alport syndrome Children Chronic kidney disease Clinical trial Enalapril Glomerular filtration rate Losartan Pediatric Proteinuria 


  1. 1.
    Avner ED, Harmon WE, Niaudet P, Yoshikawa N, Kashtan CE, Gubler MC (2009) Inherited glomerular diseases. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N (eds) Pediatric nephrology. Springer, Berlin Heidelberg New York, pp 622–628CrossRefGoogle Scholar
  2. 2.
    Gross O, Kashtan CE (2009) Treatment of Alport syndrome: beyond animal models. Kidney Int 76:599–603PubMedCrossRefGoogle Scholar
  3. 3.
    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869PubMedCrossRefGoogle Scholar
  4. 4.
    Fernandez-Andrade C, Russo D, Iversen B, Zucchelli P, Aranda P, Guerra L, Casado S (1998) Comparison of losartan and amlodipine in renally impaired hypertensive patients. Kidney Int Suppl 68:S120–S124PubMedGoogle Scholar
  5. 5.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456–1462PubMedCrossRefGoogle Scholar
  6. 6.
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860PubMedCrossRefGoogle Scholar
  7. 7.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939–945PubMedCrossRefGoogle Scholar
  8. 8.
    GISEN The Group (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349:1857–1863CrossRefGoogle Scholar
  9. 9.
    Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C (2012) Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol. doi:10.1007/s00467-012-2138-4
  10. 10.
    Webb NJ, Lam C, Shahinfar S, Strehlau J, Wells TG, Gleim GW, Le Bailly DT (2011) Efficacy and safety of losartan in children with Alport syndrome–results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant 26:2521–2526PubMedCrossRefGoogle Scholar
  11. 11.
    Webb NJ, Lam C, Loeys T, Shahinfar S, Strehlau J, Wells TG, Santoro E, Manas D, Gleim GW (2010) Randomized, double-blind, controlled study of losartan in children with proteinuria. Clin J Am Soc Nephrol 5:417–424PubMedCrossRefGoogle Scholar
  12. 12.
    Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMedGoogle Scholar
  13. 13.
    Webb NJA, Shahinfar S, Wells TG, Massaad R, Gleim GW, Santoro EP, Sisk CM, Lam C (2012) Losartan and enalapril are comparable in reducing proteinuria in children. Kidney Int. doi:10.1038/ki.2012.210
  14. 14.
    National High Blood Pressure Education Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRefGoogle Scholar
  15. 15.
    Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, Testa S, Jankauskiene A, Emre S, Caldas-Afonso A, Anarat A, Niaudet P, Mir S, Bakkaloglu A, Enke B, Montini G, Wingen AM, Sallay P, Jeck N, Berg U, Caliskan S, Wygoda S, Hohbach-Hohenfellner K, Dusek J, Urasinski T, Arbeiter K, Neuhaus T, Gellermann J, Drozdz D, Fischbach M, Moller K, Wigger M, Peruzzi L, Mehls O, Schaefer F (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361:1639–1650PubMedCrossRefGoogle Scholar
  16. 16.
    Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B, Hocker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, Dotsch J, Muller-Wiefel DE, Hoyer P, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Muller GA, Weber M (2012) Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494–501PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2012

Authors and Affiliations

  • Nicholas J. A. Webb
    • 1
  • Shahnaz Shahinfar
    • 2
    • 3
  • Thomas G. Wells
    • 4
  • Rachid Massaad
    • 5
  • Gilbert W. Gleim
    • 6
  • Christine McCrary Sisk
    • 6
  • Chun Lam
    • 6
  1. 1.Department of Paediatric Nephrology and Wellcome Trust Children’s Clinical Research Facility, Manchester Academic Health Science Centre, Royal Manchester Children’s HospitalThe University of ManchesterManchesterUK
  2. 2.S. Shahinfar Consulting Inc.Newtown SquareUSA
  3. 3.Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  4. 4.Arkansas Children’s HospitalThe University of Arkansas for Medical SciencesLittle RockUSA
  5. 5.MSD BelgiumBrusselsBelgium
  6. 6.Merck Sharp & Dohme CorpWhitehouse StationUSA

Personalised recommendations